Current Sirolimus News and Events | Page 4

Current Sirolimus News and Events, Sirolimus News Articles.
Sort By: Most Relevant | Most Viewed
Page 4 of 4 | 145 Results
Stents that release medication appear more effective than traditional stents
A type of coronary artery stent that releases a medication appears to result in better outcomes than traditional stents for heart attack patients, according to a study in the May 4 issue of JAMA. (2005-05-03)

Drug-releasing stents showing higher complication rate than clinical trials indicated
In a report in the May 4 JAMA, (2005-05-03)

Study says rare allergic reactions to drug-eluting stents may raise risk for heart attack
Since their FDA approval in 2003, stents coated with sirolimus (a pharmaceutical agent that prevents excess tissue growth) have been shown to greatly reduce restenosis. But some people suffer from rare, allergic-type reactions to the sirolimus-eluting stents (SES). (2005-03-07)

Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis
A team of Emory cardiology researchers presented a study at the American College of Cardiology (ACC) Scientific Sessions today showing that patients with in-stent restenosis treated with a sirolimus-eluting stent (SES), which releases the therapeutic agent sirolimus over time to prevent restenosis, fared at least as well as those treated with vascular brachytherapy (VB). Moreover, the patients who received the drug eluting stent had fewer cardiac events afterwards. (2005-03-07)

Single-donor islet transplantation procedure shows promise for patients with type 1 diabetes
Patients with type 1 diabetes who received islet transplantation from a single donor pancreas were insulin independent one year later, according to a study in the February 16 issue of JAMA, a theme issue on medical applications of biotechnology. (2005-02-15)

Stents and going with the flow
In the first of three articles on sirolimus-eluting stents, in the February 1 issue of CMAJ, Yang and Moussa explain the mechanism of action of these types of stents and the clinical and scientific rationale behind their use within a wider context of interventional cardiology. (2005-01-31)

Loyola study shows drug-coated stent induces less inflammation than bare metal stent
In the treatment of coronary artery disease, a sirolimus drug-coated stent causes less inflammation than bare metal stents, according to preliminary research presented at the American Heart Association annual meeting by Loyola University Health System, Maywood, Ill. (2004-11-09)

Early reports of thrombosis after insertion of drug-eluting stents
Authors of a research letter in this week's issue of The Lancet highlight how the use of drug-eluting stents (DES) may carry a risk of subsequent thrombosis if stenting is accompanied by a withdrawal of antiplatelet therapy. (2004-10-21)

Up to 6.5 million US women could benefit from new heart health advance
The first, integrated data analysis from multiple clinical trials to focus exclusively on the benefits of the Sirolimus-eluting Coronary Stent in women shows that female patients who received the CYPHER® Stent are five times more likely to avoid a repeat reblockage in the treated arteries than women treated with bare metal stents. Benefits were also seen in women with increased risks of heart disease due to diabetes and/or smoking. (2004-09-23)

Study highlights benefits of drug-eluting stents in coronary revascularisation
A pooled analysis of 11 previously published trials provides evidence that drug-eluting stents (DES)--increasingly used in coronary angioplasty--have benefits over bare-metal stents (BMS) by reducing the need for later revascularisation and reducing the risk of cardiac events. However the study did not find that the use of DES reduced the risk of death or heart attack compared with BMS. (2004-08-12)

New data supports CellCept's position as a world leader in solid organ transplantation
New data presented this week in over 70 abstracts at the American Transplant Congress in Boston, USA strengthen even further the body of evidence that CellCept® (mycophenolate mofetil, MMF) is the most reliable, efficacious, low toxic immunosuppressant for adult and paediatric kidney, heart and liver transplant patients. (2004-05-19)

Tacrolimus + mycophenolate mofetil & steroids: Safe, effective in preventing acute cardiac rejection
Late breaking data: Initial results of clinical study show tacrolimus + mycophenolate mofetil and steroids are the safest and most effective regimen in preventing acute cardiac rejection. (2004-04-23)

Insights from intravascular ultrasound explore treatment benefits
Late breaking trial data examining intravascular ultrasound (IVUS) and treatment benefits in cardiac allograft vasculopathy (thickening of arterial walls) were presented yesterday at the 24th Annual Meeting of the International Society for Heart and Lung Transplantation. (2004-04-23)

CellCept's cardioprotective profile reinforced
Data presented today at the International Society for Heart and Lung Transplantation (ISHLT) annual meeting strengthens the body of evidence that CellCept (mycophenolate mofetil, MMF) has unique benefits for heart transplant patients as the only immunosuppressant that offers superior survival benefits, reduced coronary artery disease and the least toxic side effect profile. (2004-04-22)

Heart transplant survival: Results may be key to rejection prevention, detection, treatment
Research pointing to potential victories in the battle for immune system balance in heart transplant patients will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 24th Annual Meeting, April 21-24 in San Francisco. (2004-04-19)

Drug-coated stents effective in 'real world' patients
Drug-coated stents are safe and effective at preventing death, heart attack or repeat procedures in (2003-12-22)

Study highlights efficacy of sirolimus stents to prevent restenosis for PTS with CAD
Coronary stents coated with the immunosuppressive drug sirolimus are more likely to protect patients with coronary artery disease against future narrowing of coronary arteries (restenosis) than conventional metal stetns, conclude authors of a randomised trial in this week's issue of THE LANCET. (2003-10-02)

Organ transplant recipients face serious kidney-failure risk, study finds
As if the ordeal of waiting for, receiving and living with an organ transplant weren't enough, a new study finds that people who get a second chance at life from new hearts, lungs, livers or intestines are very likely to have their lives cut short by failing kidneys. In fact, 16.5 percent of all non-kidney transplant recipients develop chronic kidney failure, and almost a third of them go on to develop full-blown end-stage renal disease. (2003-09-03)

FDA approves drug-coated stents
The US Food and Drug Administration (FDA) today approved the use of a drug-coated stent to treat patients with clogged cardiac arteries. These stents -- metal mesh tubes used as scaffolding to keep blood vessels open and unclogged -- are laced with low doses of the drug sirolimus to help prevent clogging. (2003-04-24)

New drug combination may prevent dangerous complication of bone marrow transplantation
A three-drug therapy, which includes a novel medication called sirolimus, reduces graft-versus-host disease (GVHD) in stem cell transplant patients more effectively and with less toxicity than traditional treatments, an ongoing clinical study by Dana-Farber Cancer Institute scientists suggests. Interim results of the trial, which began two years ago, will be presented by researchers at the annual meeting of the American Society of Hematology in Philadelphia on Dec. 9. (2002-12-09)

Versatile immunosuppressant drug may have new role in radiotherapy for cancer
The versatile immunosuppressant drug rapamycin may have yet another role - boosting the effectiveness of radiotherapy in cancer patients, a US doctor tells a joint European-US cancer conference in Frankfurt on Thursday 21 November. (2002-11-21)

EliTE-Symphony study recruitment begins
Senior trial investigators today announced that the first person is about to be recruited into the EliTE* (Efficacy Limiting Toxicity Elimination)-Symphony Study, the largest renal transplantation trial ever to be conducted. Patient enrollment began this month and the study aims to recruit 1300 kidney transplant patients in total, from approximately 100 sites in 17 countries worldwide. (2002-11-14)

Pill may prevent stent complication that re-blocks arteries
New research suggests that an experimental drug may hold the key to preventing restenosis, a common complication of the heart procedure called stenting, which uses tiny mesh tubes to prop open clogged arteries. The findings are reported in today's rapid access issue of Circulation: Journal of the American Heart Association. (2002-09-30)

Preliminary US study findings support excellent results with CYPHER Sirolimus-eluting Stent
Clinical investigators today reported preliminary findings at The Paris Course on Revascularization (PCR) documenting the excellent results of the CYPHER™ Sirolimus-eluting Stent in the first 400 patients enrolled in the landmark SIRIUS study. SIRIUS is a large-scale, randomized, double-blind, controlled clinical trial involving 53 U.S. treatment centers and 1,101 patients. The study was sponsored by Cordis Corporation, a Johnson & Johnson company. (2002-05-22)

Stanford researcher dusts off old drug; uncovers new anti-rejection properties
Thirty years ago, researchers scooped some dirt on Easter Island and discovered bacteria that led to a potential anti-fungal drug. Little did they know that the drug - which languished on shelves after proving ineffective in early trials - would become popular in 1999 as a way to prevent rejection of transplanted organs. Now, new studies from Stanford University Medical Center have found that the drug can also protect blood vessels of transplanted hearts, preventing the leading cause of heart transplant failure. (2002-04-25)

Page 4 of 4 | 145 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.